↓ Skip to main content

The Effect of a Cardiovascular Polypill Strategy on Pill Burden

Overview of attention for article published in Cardiovascular Therapeutics, November 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (62nd percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

1 policy source


18 Dimensions

Readers on

70 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
The Effect of a Cardiovascular Polypill Strategy on Pill Burden
Published in
Cardiovascular Therapeutics, November 2015
DOI 10.1111/1755-5922.12151
Pubmed ID

Michael Truelove, Anushka Patel, Severine Bompoint, Alex Brown, Alan Cass, Graham S. Hillis, David Peiris, Natasha Rafter, Christopher M. Reid, Anthony Rodgers, Andrew Tonkin, Tim Usherwood, Ruth Webster


Recent trials of cardiovascular polypills in high-risk populations show improvements in use of cardiovascular preventive treatments, compared to usual care. We describe patterns of pill burden in Australian practice, define the impact of polypill therapy on pill burden and explore how physicians add medication to polypill therapy. The Kanyini Guidelines Adherence with the Polypill study was an open-label trial involving 623 participants in Australia which randomised participants to a polypill strategy (containing a statin, anti-platelet agent and 2 blood pressure lowering medications) or usual care. Participants either had established cardiovascular disease or were at high calculated risk (≥ 15% over 5 years). Current medications, daily pill burden, and self-reported use of combination treatment were recorded prior to randomisation and at study end. Median pill burden at baseline and study end were compared in both arms. Subgroup analysis of the polypill strategy on trial primary outcomes was conducted by pill burden at baseline. Median total and cardiovascular pill burdens of the polypill group decreased from 7 to 5 and from 4 to 2 respectively (median change -2; IQR -3, 0) with no change in the usual care group (comparison of change; p<0.001). No change was seen for non-cardiovascular medications. Of those still using the polypill at study end, 43.8% were prescribed additional medications; 84.5% of these additional medications were blood pressure lowering medications. Within the polypill group, lower pill burden at baseline was associated with greater increases in the use of indicated cardiovascular preventive medications at study end compared to those with higher pill burdens. No trend was observed between the level of baseline pill burden and the effect of poylpill treatment on systolic blood pressure or total cholesterol. A cardiovascular polypill in contemporary Australian practice reduces cardiovascular and total pill burdens, despite frequent prescription of additional medications. This article is protected by copyright. All rights reserved.

Mendeley readers

The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 1%
Unknown 69 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 21%
Student > Bachelor 10 14%
Researcher 9 13%
Student > Doctoral Student 5 7%
Student > Postgraduate 4 6%
Other 12 17%
Unknown 15 21%
Readers by discipline Count As %
Medicine and Dentistry 22 31%
Pharmacology, Toxicology and Pharmaceutical Science 7 10%
Sports and Recreations 3 4%
Agricultural and Biological Sciences 3 4%
Psychology 3 4%
Other 10 14%
Unknown 22 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2017.
All research outputs
of 12,002,078 outputs
Outputs from Cardiovascular Therapeutics
of 203 outputs
Outputs of similar age
of 259,187 outputs
Outputs of similar age from Cardiovascular Therapeutics
of 9 outputs
Altmetric has tracked 12,002,078 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 203 research outputs from this source. They receive a mean Attention Score of 4.6. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 259,187 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.